You are viewing: France Multiomics Market analysis
Part of: Multiomics Market (Global)

The France Multiomics Market was valued at $101.3 Million in 2026 and projected to reach to $172.3 Million by 2031, representing a compound annual growth rate of 11.2%. France's multiomics market is poised for significant expansion as healthcare providers increasingly recognize the value of integrated omics data in clinical decision-making and drug development.

France Multiomics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Multiomics Market Trends and Insights

  • France is experiencing accelerating adoption of integrated omics technologies driven by advances in genomics, proteomics, and metabolomics platforms that enable comprehensive disease understanding and personalized medicine approaches.
  • The French healthcare system's emphasis on precision diagnostics and research innovation is fueling demand for multiomics solutions across clinical and research institutions. The 11.2% compound annual growth rate reflects France's commitment to modernizing its diagnostic infrastructure and supporting biotechnology innovation hubs.
  • France is leveraging European regulatory frameworks and collaborative research initiatives to strengthen its multiomics capabilities.
  • By 2031, France is expected to consolidate its position as a regional leader in multiomics adoption, supported by increased investment in life sciences research and growing clinical applications in oncology, rare diseases, and cardiovascular medicine..

Key Market Statistics

  • CAGR (2026-2031) 11.2% CAGR
  • Market Size, 2026 ~USD 101.3 Million
  • Forecast, 2031 ~USD 172.3 Million
  • Country France

France Multiomics Market Overview

Market Valuation Growth :

France's multiomics market is valued at $101.3 million in 2026 and is projected to reach $172.3 million by 2031, representing a robust 11.2% CAGR over the forecast period.

European Leadership Position :

France is establishing itself as a key growth segment within European healthcare, leveraging its advanced research infrastructure and strong pharmaceutical ecosystem to drive multiomics adoption.

Technology Integration Acceleration :

French healthcare institutions are rapidly adopting integrated omics technologies spanning genomics, proteomics, and metabolomics, enabling comprehensive disease understanding and precision medicine applications.

Personalized Medicine Momentum :

The French market is experiencing accelerating demand for personalized medicine solutions, with multiomics platforms enabling tailored therapeutic approaches and improved patient outcomes across multiple disease areas.

France Multiomics Market Dynamics

  • The 11.2% CAGR reflects growing investments in precision medicine infrastructure, coupled with supportive regulatory frameworks and collaborative research initiatives across French academic and commercial institutions. Key drivers include rising adoption among pharmaceutical companies conducting biomarker research, expanding clinical applications in oncology and rare diseases, and strengthening partnerships between French biotech firms and international multiomics platform providers.
  • Government support for genomic medicine initiatives and increasing reimbursement for omics-based diagnostics will further accelerate market penetration through 2031..

Market Ecosystem

logo-mobile

MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina)
company logo
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • France's multiomics market is valued at $101.3 million in 2026 and is forecast to reach $172.3 million by 2031, representing a robust 11.2% CAGR.
    • France is driving multiomics adoption through precision medicine initiatives and increased investment in genomics and proteomics research infrastructure.
    • Clinical applications in France are expanding across oncology, rare disease diagnosis, and cardiovascular medicine, supported by regulatory alignment with European standards.
    • France's position within the European healthcare ecosystem positions it as a regional hub for multiomics innovation and technology adoption through 2031.

    Multiomics Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment SERVICES (Offering)
    Forecast Period 2026-2031
    Growth Rate CAGR of 12.3% from 2026 to 2031
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 3.19 (2026)
    Revenue Forecast (Billions) ~USD 5.7 (2031)
    Segments Covered Offering, Type, Technology, Method, Workflow, Application, End User

    France Multiomics Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services

    By Type

    • Assay Kits & Reagents
    • Consumables
    • Instruments & Software
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Nanopore Sequencing
    • Ngs-Based Proteomics
    • Other Consumables
    • Other Proteomics Methods
    • Other Sequencing Technologies
    • Pcr-Based Proteomics
    • Smrt Sequencing

    By Technology

    • Long-Read Sequencing
    • Nanopore Sequencing
    • Other Sequencing Technologies
    • Other Technologies
    • Proteomics
    • Sequencing
    • Smrt Sequencing

    By Method

    • Chromatin Accessibility Sequencing
    • Chromatin Interaction Analysis
    • Dna Methylation Sequencing
    • Epigenomics
    • Histone Modification Profiling
    • Long-Range Sequencing
    • Long-Read & Long-Range Sequencing
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Ngs-Based Proteomics
    • Other Epigenomics Methods
    • Other Long-Read & Long-Range Sequencing Methods
    • Other Methods
    • Other Proteomics Methods
    • Other Single-Cell Omics
    • Other Spatial Omics
    • Pcr-Based Proteomics
    • Proteomics
    • Sequencing-Based Epigenomics
    • Single-Cell Epigenomics
    • Single-Cell Genomics
    • Single-Cell Omics
    • Single-Cell Proteomics
    • Single-Cell Transcriptomics
    • Spatial Epigenomics
    • Spatial Genomics
    • Spatial Omics
    • Spatial Proteomics
    • Spatial Transcriptomics

    By Workflow

    • Data Visualization & Analysis
    • Sample Preparation
    • Sequencing & Analysis/ Sample Characterization
    • Sequencing & Analysis/Sample Characterization

    By Application

    • Biomarker Discovery
    • Cell Biology
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Immunology
    • Neurology
    • Oncology
    • Other Applications
    • Precision Medicine
    • Translational Research

    By End User

    • Academic & Research Institutes
    • Cros & Cdmos
    • Hospitals & Diagnostic/Clinical Laboratories
    • Pharmaceutical & Biotechnology Companies

    Target Audience

    • Pharmaceutical & Biotech Companies : French and international pharma firms need market intelligence to guide R&D investments, biomarker strategy development, and commercial planning for multiomics-enabled drug development in France.
    • Diagnostic & Omics Platform Providers : Multiomics technology vendors require France-specific market data to assess commercial opportunity, identify hospital and research institution targets, and develop localized go-to-market strategies.
    • Healthcare System Decision-Makers : French hospital networks, health authorities, and clinical laboratory directors need market insights to evaluate multiomics integration, budget for technology adoption, and plan precision medicine programs.
    • Investment & Private Equity Firms : Investors targeting French biotech and healthcare sectors require detailed market analysis to identify high-growth multiomics companies, assess valuation multiples, and evaluate acquisition targets.
    • Academic & Research Institutions : French universities and research centers need market data to secure funding, justify multiomics infrastructure investments, and position themselves as leaders in precision medicine research and innovation.

    Reasons to Buy this Report

    • Market-Specific Sizing & Forecasts : Access precise valuation data for France's multiomics market with detailed 2026-2031 projections, enabling accurate budget allocation and investment planning tailored to the French healthcare landscape.
    • Competitive Landscape Intelligence : Understand France-specific market dynamics, key players, and competitive positioning within European multiomics adoption, identifying partnership and expansion opportunities in this high-growth segment.
    • Regulatory & Reimbursement Insights : Gain clarity on French healthcare policies, reimbursement frameworks, and regulatory pathways for multiomics diagnostics and therapeutics, critical for market entry and commercialization strategies.
    • Clinical Adoption Trends : Identify which French healthcare institutions are leading multiomics adoption, understand clinical applications gaining traction, and benchmark against European peers to inform go-to-market strategies.
    • Growth Driver Analysis : Discover France-specific catalysts including government genomic initiatives, pharmaceutical R&D investments, and precision medicine adoption rates that will shape market expansion through 2031.

    Frequently asked questions

    What is the current size of France's multiomics market?

    France's multiomics market is valued at $101.3 million in 2026 and is expected to grow to $172.3 million by 2031.

    What is the growth rate of the multiomics market in France?

    France's multiomics market is growing at a compound annual growth rate (CAGR) of 11.2% from 2026 to 2031.

    Which clinical applications are driving multiomics adoption in France?

    France is seeing increased multiomics adoption in oncology, rare disease diagnosis, and cardiovascular medicine, supported by precision medicine initiatives and research funding.

    How does France's multiomics market compare to other European countries?

    France is positioned as a regional leader in multiomics adoption within Europe, leveraging its strong life sciences research ecosystem and healthcare infrastructure to drive market growth.

    What factors are supporting multiomics market growth in France?

    France's multiomics growth is supported by advances in genomics and proteomics technologies, increased research investment, regulatory alignment with European standards, and growing clinical demand for precision diagnostics.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Multiomics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Multiomics Market : Top-Down and Bottom-Up Approach

    Multiomics Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

    Market Definition

    The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.

    Key Stakeholders

    • Multiomics product & service providers
    • Multiomics bioinformatics/data analysis companies
    • Venture capitalists and other government funding organizations
    • Research and consulting firms
    • Hospitals and diagnostic clinics
    • Pharmaceutical and biotechnology companies
    • Academic and government research institutes
    • Life science companies

    Report Objectives

    • To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market shares and core competencies
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe multiomics market, by country
    • Further breakdown of the Rest of Asia Pacific multiomics market, by country

    Company Analysis

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

    Get the Full Multiomics Market Report

    Full forecast, segment splits, and company analysis for all Multiomics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status